Jagsonpal Pharmaceuticals Ltd vs Lyka Labs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Jagsonpal Pharmaceuticals Ltd is ₹ 210.3 as of 30 Apr 15:30 . The P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Lyka Labs Ltd changed from 10 on March 2022 to 45.1 on March 2025 . This represents a CAGR of 45.73% over 4 years The Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Lyka Labs Ltd changed from ₹ 74.59 crore on March 2021 to ₹ 360.29 crore on March 2025 . This represents a CAGR of 37.02% over 5 years The revenue of Jagsonpal Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Lyka Labs Ltd for the Dec '25 is ₹ 31.89 crore as compare to the Sep '25 revenue of ₹ 37.75 crore. This represent the decline of -15.52% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Lyka Labs Ltd for the Dec '25 is ₹ 2.81 crore as compare to the Sep '25 ebitda of ₹ -1.45 crore. This represent the decline of -293% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Lyka Labs Ltd changed from ₹ 1.29 crore to ₹ -0.15 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 15.36 % on March 2021 to 29.99 % on March 2025 . This represents a CAGR of 14.32% over 5 yearsThe Dividend Payout of Lyka Labs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

About Lyka Labs Ltd

Initially manufacturing formulations, Lyka Labs Limited brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. '83.
It also added a range of ayurvedic and animal health care products over the years.
In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan.
Lyka Exports is the subsidiary of the company.
The Company is engaged in the development, manufacture and marketing of quality finished dosages. The company offers a broad range of antibiotics used as life-savers and to treat minor infections.

FAQs for the comparison of Jagsonpal Pharmaceuticals Ltd and Lyka Labs Ltd

Which company has a larger market capitalization, Jagsonpal Pharmaceuticals Ltd or Lyka Labs Ltd?

Market cap of Jagsonpal Pharmaceuticals Ltd is 1,411 Cr while Market cap of Lyka Labs Ltd is 215 Cr

What are the key factors driving the stock performance of Jagsonpal Pharmaceuticals Ltd and Lyka Labs Ltd?

The stock performance of Jagsonpal Pharmaceuticals Ltd and Lyka Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jagsonpal Pharmaceuticals Ltd and Lyka Labs Ltd?

As of May 3, 2026, the Jagsonpal Pharmaceuticals Ltd stock price is INR ₹210.3. On the other hand, Lyka Labs Ltd stock price is INR ₹60.49.

How do dividend payouts of Jagsonpal Pharmaceuticals Ltd and Lyka Labs Ltd compare?

To compare the dividend payouts of Jagsonpal Pharmaceuticals Ltd and Lyka Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.